Skip to content
October 26, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Kanker Payudara

Kanker Payudara

Primary Menu
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Watch
  • Home
  • Breast Cancer Surgery and Reconstruction
  • The Hidden Risk: How Recent Antibiotic Use May Complicate Breast Reconstruction Outcomes
  • Breast Cancer Surgery and Reconstruction

The Hidden Risk: How Recent Antibiotic Use May Complicate Breast Reconstruction Outcomes

Neng Nana May 25, 2026 7 minutes read
0
the-hidden-risk-how-recent-antibiotic-use-may-complicate-breast-reconstruction-outcomes

For thousands of women navigating the complex journey of breast cancer recovery, surgical reconstruction is a pivotal step toward reclaiming their quality of life. Among the most common procedures is the placement of tissue expanders—a technique that uses a balloon-like device to gradually stretch the skin and underlying tissues, preparing the site for a permanent implant. While this procedure is routine, it carries a significant risk of surgical site infections (SSIs).

A landmark study published in the February issue of Plastic and Reconstructive Surgery®, the official journal of the American Society of Plastic Surgeons (ASPS), has uncovered a counterintuitive and concerning risk factor for these infections: the recent use of antibiotics. According to the research, patients who took antibiotics within 30 days of their reconstruction surgery face a nearly four-fold increase in the risk of developing a post-operative infection, casting new light on the delicate balance of the human microbiome and its role in surgical recovery.


Main Facts: A Counterintuitive Discovery

The study, led by Dr. Bernard T. Lee of Beth Israel Deaconess Medical Center and Harvard Medical School, challenges the traditional assumption that antibiotic use—even in the weeks leading up to an operation—is a purely protective measure.

The core finding is that patients exposed to antibiotics in the 30-day window prior to their tissue expander surgery were 3.91 times more likely to develop an SSI within the first month post-operation compared to those who were not. This suggests that the very medication intended to prevent infection may, in some cases, be inadvertently compromising the patient’s natural defenses.

The proposed mechanism behind this phenomenon is "dysbiosis"—a disruption of the body’s normal bacterial flora. When antibiotics are administered, they do not discriminate exclusively between "bad" and "good" bacteria. By thinning out the protective microbial communities that inhabit the skin and other tissues, these drugs may create an environment where pathogenic or antibiotic-resistant bacteria can thrive, ultimately leading to higher infection rates when the skin is disrupted during surgery.


Chronology: The Evolution of the Research

The investigation into this phenomenon followed a rigorous, evidence-based trajectory:

  1. Observation: Surgeons have long noted that despite the administration of prophylactic antibiotics during surgery, infection rates in tissue expander procedures remained higher than desired. Researchers began to question if external factors, such as the patient’s recent medical history, were contributing to these failures.
  2. Database Assembly: Dr. Lee and his team utilized a comprehensive research database to identify a cohort of patients undergoing tissue expander-based breast reconstruction.
  3. The Matching Process: To ensure scientific accuracy, the researchers created two distinct groups of 1,383 patients each. One group had received antibiotics in the 30 days prior to surgery, while the control group had not. To eliminate confounding variables, the teams were "propensity score-matched," meaning they were balanced for known infection risk factors such as obesity, smoking, diabetes, and breast cancer stage.
  4. Analysis: The research team tracked these patients through the 30-, 60-, and 90-day post-operative windows to monitor for infections, wound dehiscence (the separation of surgical edges), and the necessity for device removal.
  5. Publication: The final results, published in the February 2026 issue of Plastic and Reconstructive Surgery, provided the first clinical data linking preoperative antibiotic exposure to negative surgical outcomes in this specific field.

Supporting Data: By the Numbers

The statistical significance of the findings is striking, providing a clear warning for both practitioners and patients. The following data points highlight the elevated risks associated with recent antibiotic use:

  • Relative Risk (RR) of SSI: Patients in the exposed group were 3.91 times more likely to experience an infection in the first 30 days.
  • Wound Healing Complications: The risk of wound dehiscence—a common precursor to infection where the surgical incision fails to heal properly—was approximately double in the exposed group.
  • Device Failure: The probability of needing to remove the tissue expander due to complications was significantly higher for those who had recently used antibiotics.
  • Extended Impact: The researchers observed that while the infection risk began to decrease after 30 days, it remained elevated through the 60- and 90-day follow-up assessments. This persistent risk curve suggests that the gut and skin microbiome may take several months to fully recover from a course of antibiotics.
  • Post-Operative Antibiotic Reliance: Interestingly, patients who had used antibiotics before surgery were more likely to be prescribed additional antibiotics after the surgery, potentially creating a cycle of dysbiosis that hinders natural healing.

Official Responses and Clinical Perspectives

Dr. Bernard T. Lee, the study’s lead investigator, emphasized the importance of this discovery for the field of reconstructive surgery. "For plastic surgeons, the findings suggest the need for careful assessment of antibiotic use in patients undergoing tissue expander-based breast reconstruction," Dr. Lee stated. He further noted that the findings do not necessarily demand an immediate halt to all antibiotic prescriptions, but they do require a "careful assessment of the risk-to-benefit ratio" before proceeding with surgery.

The American Society of Plastic Surgeons (ASPS) has signaled that these findings warrant further investigation. The medical community is now calling for randomized clinical trials to confirm these results. Such trials could help define whether there is a "safe" waiting period between a completed course of antibiotics and the date of surgery, or if specific classes of antibiotics are more detrimental to the microbiome than others.

Experts in the field are also considering the potential for "microbiome management." As researchers look toward the future, the use of targeted probiotics or prebiotics to restore the protective bacterial balance before elective surgery may become a topic of intense clinical interest.


Implications for Future Medical Practice

The implications of this study extend well beyond breast reconstruction. If preoperative antibiotic use can increase infection rates in tissue expansion, it is highly likely that similar risks exist for other surgical specialties, including orthopedic and general surgery.

Changing the Standard of Care

The traditional medical model often leans toward "better safe than sorry," frequently prescribing antibiotics for minor ailments or as a precautionary measure. This study suggests that in the context of major elective surgery, that precaution may be counterproductive. Physicians may need to start keeping a detailed "microbiome history" for their patients, delaying elective procedures for patients who have recently completed a course of broad-spectrum antibiotics.

The Need for Proactive Patient Education

Patients also have a role to play. Women preparing for breast reconstruction should be encouraged to disclose all recent medication use, including over-the-counter or urgent-care antibiotic prescriptions. Awareness that these drugs can have long-lasting effects on the body’s surgical readiness is a critical component of informed consent.

Future Research Directions

The research team has identified several areas for future study:

  • Defining the "Washout" Period: Determining the exact number of days required for the microbiome to stabilize after antibiotic treatment.
  • Microbial Profiling: Investigating whether specific bacterial species are lost during antibiotic use that are essential for skin-site immunity.
  • Probiotic Intervention: Examining whether patients who take high-quality, targeted probiotics after antibiotic use show a lower risk of post-surgical complications.

In conclusion, while tissue expanders remain a vital tool for breast reconstruction, the study from Plastic and Reconstructive Surgery serves as a sobering reminder of the complexity of human biology. As we continue to refine surgical techniques, we must also respect the delicate, invisible ecosystems that reside within us. The goal of every surgeon is to provide the best possible outcome for their patient; sometimes, the most effective way to help the body heal is to avoid disrupting the protective forces that are already there.


For more information on the study, "Recent Antibiotic Use and Surgical Site Infections in Tissue Expander–Based Breast Reconstruction: A Propensity Score–Matched Analysis," readers are encouraged to consult the February 2026 issue of Plastic and Reconstructive Surgery or access the full text via the Wolters Kluwer portal.

About the Author

Neng Nana

Author

View All Posts

Post navigation

Previous: Navigating Childhood Through the Storm: A Parent’s Guide to Supporting Children During Cancer Treatment
Next: Breakthrough in Glioblastoma Treatment: Keck Medicine of USC Researchers Uncover Promising Triple Therapy

Related Stories

enhancing-the-standard-of-care-the-breast-surgery-collaborative-community-proposes-streamlined-fda-patient-decision-checklist
  • Breast Cancer Surgery and Reconstruction

Enhancing the Standard of Care: The Breast Surgery Collaborative Community Proposes Streamlined FDA Patient Decision Checklist

Azzam Bilal Chamdy October 26, 2026
beyond-implants-the-rise-of-autologous-fat-transfer-in-post-mastectomy-breast-reconstruction-23
  • Breast Cancer Surgery and Reconstruction

Beyond Implants: The Rise of Autologous Fat Transfer in Post-Mastectomy Breast Reconstruction

Suro Senen October 25, 2026
advancing-the-art-and-science-of-surgery-dr-sara-r-dickie-named-president-of-the-plastic-surgery-foundation
  • Breast Cancer Surgery and Reconstruction

Advancing the Art and Science of Surgery: Dr. Sara R. Dickie Named President of The Plastic Surgery Foundation

Raul Delapena Setiawan October 25, 2026

Recent Posts

  • Revolutionizing Breast Cancer Screening: Landmark Study Advocates Personalized Risk-Based Approach Over Universal Guidelines
  • ESMO26: Amgen’s Imdelltra posts win in first-line SCLC maintenance setting
  • Nourishing Hope: How Real Food Can Be a Powerful Ally in the Fight Against Breast Cancer
  • METAvivor President Dr. Kelly Shanahan Navigates Treatment Shift as Organization Launches Major Fall Initiatives
  • Global Scientific Vanguard: BCRF Hosts Record-Breaking Conference to Accelerate Breast Cancer Eradication

Recent Comments

No comments to show.

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • September 2025
  • August 2025
  • July 2025

Categories

  • Breast Cancer Legislation and Policy
  • Breast Cancer Prevention and Lifestyle
  • Breast Cancer Surgery and Reconstruction
  • Chemotherapy and Targeted Therapy
  • Clinical Oncology Education
  • Clinical Radiology and Imaging
  • Genomics and Precision Medicine
  • Global Breast Cancer Awareness
  • Hormone Therapy and Endocrinology
  • Integrative Oncology and Holistic Care
  • Medical Research and Clinical Trials
  • Metastatic Breast Cancer Research
  • Patient Advocacy and Support
  • Psychosocial Support and Mental Health
  • Radiation Oncology
  • Survivorship and Post-Treatment
  • Treatment Innovations

You may have missed

revolutionizing-breast-cancer-screening-landmark-study-advocates-personalized-risk-based-approach-over-universal-guidelines
  • Medical Research and Clinical Trials

Revolutionizing Breast Cancer Screening: Landmark Study Advocates Personalized Risk-Based Approach Over Universal Guidelines

Dwi Wanna October 26, 2026
esmo26-amgens-imdelltra-posts-win-in-first-line-sclc-maintenance-setting
  • Medical Research and Clinical Trials

ESMO26: Amgen’s Imdelltra posts win in first-line SCLC maintenance setting

Nana October 26, 2026
nourishing-hope-how-real-food-can-be-a-powerful-ally-in-the-fight-against-breast-cancer
  • Patient Advocacy and Support

Nourishing Hope: How Real Food Can Be a Powerful Ally in the Fight Against Breast Cancer

Layla Zulfa October 26, 2026
metavivor-president-dr-kelly-shanahan-navigates-treatment-shift-as-organization-launches-major-fall-initiatives
  • Patient Advocacy and Support

METAvivor President Dr. Kelly Shanahan Navigates Treatment Shift as Organization Launches Major Fall Initiatives

Asro October 26, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Copyright © All rights reserved. | MoreNews by AF themes.